Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review

Jurgen Sota, Donato Rigante, Giuseppe Lopalco, Bruno Frediani, Rossella Franceschini, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Claudia Fabiani, Luca Cantarini

Research output: Contribution to journalReview article

Abstract

Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.

Original languageEnglish
Pages (from-to)25-35
Number of pages11
JournalRheumatology International
Volume38
Issue number1
DOIs
Publication statusPublished - Jan 2018

Fingerprint

Biological Therapy
Uveitis
Eye Manifestations
Tumor Necrosis Factor-alpha
Eye Diseases
Biological Factors
Antigen-Antibody Complex
Interleukin-1
Veins
Interleukin-6
Arteries
Inflammation
Therapeutics
Rituximab
secukinumab
daclizumab
alemtuzumab
Erythema elevatum diutinum
Ustekinumab

Keywords

  • Behcet Syndrome/complications
  • Biological Products/therapeutic use
  • Humans
  • Interleukin-1/antagonists & inhibitors
  • Interleukin-6/antagonists & inhibitors
  • Treatment Outcome
  • Uveitis/drug therapy

Cite this

Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade : a narrative review. / Sota, Jurgen; Rigante, Donato; Lopalco, Giuseppe; Frediani, Bruno; Franceschini, Rossella; Galeazzi, Mauro; Iannone, Florenzo; Tosi, Gian Marco; Fabiani, Claudia; Cantarini, Luca.

In: Rheumatology International, Vol. 38, No. 1, 01.2018, p. 25-35.

Research output: Contribution to journalReview article

Sota, J, Rigante, D, Lopalco, G, Frediani, B, Franceschini, R, Galeazzi, M, Iannone, F, Tosi, GM, Fabiani, C & Cantarini, L 2018, 'Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review', Rheumatology International, vol. 38, no. 1, pp. 25-35. https://doi.org/10.1007/s00296-017-3775-5
Sota, Jurgen ; Rigante, Donato ; Lopalco, Giuseppe ; Frediani, Bruno ; Franceschini, Rossella ; Galeazzi, Mauro ; Iannone, Florenzo ; Tosi, Gian Marco ; Fabiani, Claudia ; Cantarini, Luca. / Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade : a narrative review. In: Rheumatology International. 2018 ; Vol. 38, No. 1. pp. 25-35.
@article{0c3e478ab0fa458e8facf37fe8e3e4fd,
title = "Biological therapies for the treatment of Beh{\cc}et's disease-related uveitis beyond TNF-alpha blockade: a narrative review",
abstract = "Intraocular inflammation is one of the more relevant complications of Beh{\cc}et's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.",
keywords = "Behcet Syndrome/complications, Biological Products/therapeutic use, Humans, Interleukin-1/antagonists & inhibitors, Interleukin-6/antagonists & inhibitors, Treatment Outcome, Uveitis/drug therapy",
author = "Jurgen Sota and Donato Rigante and Giuseppe Lopalco and Bruno Frediani and Rossella Franceschini and Mauro Galeazzi and Florenzo Iannone and Tosi, {Gian Marco} and Claudia Fabiani and Luca Cantarini",
year = "2018",
month = "1",
doi = "10.1007/s00296-017-3775-5",
language = "English",
volume = "38",
pages = "25--35",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade

T2 - a narrative review

AU - Sota, Jurgen

AU - Rigante, Donato

AU - Lopalco, Giuseppe

AU - Frediani, Bruno

AU - Franceschini, Rossella

AU - Galeazzi, Mauro

AU - Iannone, Florenzo

AU - Tosi, Gian Marco

AU - Fabiani, Claudia

AU - Cantarini, Luca

PY - 2018/1

Y1 - 2018/1

N2 - Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.

AB - Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.

KW - Behcet Syndrome/complications

KW - Biological Products/therapeutic use

KW - Humans

KW - Interleukin-1/antagonists & inhibitors

KW - Interleukin-6/antagonists & inhibitors

KW - Treatment Outcome

KW - Uveitis/drug therapy

U2 - 10.1007/s00296-017-3775-5

DO - 10.1007/s00296-017-3775-5

M3 - Review article

C2 - 28752230

VL - 38

SP - 25

EP - 35

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 1

ER -